Apollo Hospitals Share Price: The stock of Apollo Hospitals rose by 1.57 on BSE on Wednesday (August 14, 2024) a day after the hospital chain reported an 83 per cent jump in its profit after tax in Q1 results. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Apollo Hospitals shares that closed the trading session at Rs 6,586.55 apiece a day ago rose to Wednesday's high of Rs 6,690.20 each, a 1.57 per cent rise from its previous close. 

The stock was trading higher by 1.04 per cent, or Rs 68.75, at Rs 6,655.30, at 10:09 am on Wednesday.

Apollo Hospitals share price history

The Apollo Hospitals stock has soared by 39.56 per cent in 1 year, while its rise year to date is 16.99 per cent.

Nifty 50, meanwhile, has risen by 24.23 per cent in 1 year, while its YTD rise is 11.05 per cent.

Apollo Hospitals 52-week high is Rs 6,871.30. 

Apollo Hospitals 52-week low is Rs 4,727.00.

Apollo Hospitals Q1 results: Profit soars

Apollo Hospitals on Tuesday posted an 83 per cent jump in its consolidated profit after tax to Rs 305 crore for the first quarter ended June 30. The rise was aided by robust performance across business verticals, the company said in a statement.

The healthcare firm reported a profit after tax of Rs 167 crore in the June quarter of FY24.

Its revenue rose to Rs 5,086 crore for the first quarter against Rs 4,418 crore in the April-June quarter of last fiscal.

Brokerages on Apollo Hospitals

Citi on Apollo Hospital (CMP Rs 6,589)

Citi has maintained a 'buy' call on the stock with a target of Rs 7,670.

It says that the company's Q1 result is healthy and in-line 

Hospitals growth was largely driven by IP volumes though ARPOB growth was a bit muted, it says.

Citi opines AHLL witnessed margin improvement in diagnostics/primary care.

In Healthco, offline pharmacy distribution margins were slightly subdued, says the brokerage firm.
 

Macquarie on Apollo Hospital (CMP Rs 6,589)

Macquarie has maintained an 'underperform' with a target of Rs 5,040.

Its 1Q revenue and PAT is largely in line, says the brokerage, adding that the firm missed its EBITDA estimate by 6 per cent.

Overall, EBITDA margin of 13.3 per cent came below estimate of 14 per cent.